Bucharest, Romania, 4 March, 2024: Affidea Group, Europe’s largest provider of advanced
diagnostics, multi-speciality polyclinics and Centres of Excellence, announced today that it has
entered into a binding agreement to acquire MedEuropa Romania, a renowned cancer care
provider.
MedEuropa Romania operates four medical centres in Romania, spanning Constanta, Bucharest,
Brasov, and Oradea, with two further centres set to open in Iasi and Bacau during 2024. The company
is renowned for its expertise in advanced cancer care, including Radiotherapy, Chemotherapy and
broader oncology services, all of which integrate into Affidea’s primary diagnostic and polyclinic
portfolio in Romania. The acquisition adds radiotherapy services to Affidea’s capability in Romania,
complementing existing radiotherapy services that Affidea provides across its European footprint.
Philippe Jacobs, Chairman and Silviu Savin, CEO of MedEuropa commented: “We are proud to have
built a greenfield network of clinics providing high quality patient care and treatments across Romania.
We would like to thank our doctors and staff for their contributions over the past years. We believe
that an integrated care solution is optimal for oncology patients and therefore see the integration of
MedEuropa in the larger Affidea family as an ideal avenue for delivering the best care and results for
cancer patients in Romania.”
Razvan Predica, Country CEO for Affidea Romania and Hungary, stated: “Cancer is claiming far too
many lives in our communities, with approximately 100,000 people being diagnosed with an
oncological disease in Romania every year. This acquisition isn’t just about growth; it’s about standing
shoulder-to-shoulder with the National Health System and those affected by this relentless disease.
We look forward to working with the great team of MedEuropa following the closing and continue
delivering value for every individual impacted by cancer by increasing access to more comprehensive
cancer care pathway from diagnosis to treatment and follow-up.
Guy Blomfield, CEO and Chairman of the Management Board for Affidea Group, added: “At Affidea,
we have a provenance in the provision of comprehensive cancer care pathways across several
European countries, with a network of Community Clinics and Centres of Excellence which are
dedicated to providing access and high-quality care to the patient communities we serve. Romania’s
healthcare market is embracing the challenge of improving cancer survivorship outcomes, and
Affidea’s integrated service model will have an important role in helping to improve early detection
and diagnosis, as well as providing more access to radiotherapy services in community settings across
Romania. Affidea and MedEuropa, both have impressive reputations for high quality patient care, and
I am very confident that the integration of services will further enhance outcomes for oncology patients
across Romania.
Completion of the acquisition is subject to the approval of the Romanian Competition Council. Affidea
Group was advised by Rizoiu & Asociatii and Clifford Chance as legal advisors, while Deloitte served as
financial advisor. The sellers were advised by Biris Goran and Linklaters as legal advisors.
About MedEuropa
Telemos Capital in partnership with a local team of entrepreneurs, established MedEuropa to address the undersupplied Romanian radiotherapy market, with a vision of building a greenfield network of clinics across the
country. MedEuropa is committed to providing state of the art cancer treatment, with a strong focus on
radiotherapy. The company operates four clinics across Romania (in Brasov, Bucharest, Constanta and Oradea)
and is constructing additional clinics and treatment centres in Iasi (opening planned in Q1 2024), Bacau, Brasov,
and Bistrita.
About Telemos Capital
Telemos Capital (www.telemoscapital.com) invests in private European businesses, with the aim of building
great companies for the long term. Funded by family capital, it combines the flexibility and nimble decisionmaking of a family office with the active ownership and professionalism of private equity. Telemos seeks to
acquire majority stakes in businesses with the potential for sustainable growth through international
expansion, add-on acquisitions or operational improvements. Other Telemos investments in the Healthcare
Services sector include Stingray and Sanoptis (exited in 2022).
About Affidea Romania
Affidea Romania is one of the leading healthcare providers across the country, offering advanced diagnostics,
laboratory analysis and multi-specialty consultations, with 50 medical centres in 26 cities. The Affidea Romania
team consists of more than 1,500 professionals, out of which over 900 clinicians, annually providing integrated
medical services for more than 2 million patients.
About Affidea Group
Affidea (www.affidea.com) is the largest European provider of advanced diagnostic imaging, out-of-hospital and
cancer care services. Founded in 1991, the company operates 355 centres across 15 countries, providing highquality medical services to nearly 13 million patients every year. Due to its track record for patient safety, the
company has become the most awarded diagnostic imaging provider in Europe by the European Society of
Radiology, as over 80% of the centres recognised on the Eurosafe Wall of Stars belong to Affidea. Affidea is
majority-owned by Groupe Bruxelles Lambert (GBL), a leading investment holding company, focused on longterm value-creation with a stable and supportive family shareholder base.
